Elevated serum osteopontin levels in chronic hepatitis c virus infection: Association with autoimmune rheumatologic manifestations

Journal of Clinical Immunology

Volumn 32, Issue 6, 2012, Pages 1262-1269

  Bassyouni, Iman H ^a,d   Bassyouni, Rasha H ^b   Ibrahim, Nermin H ^c   Soliman, Ahmed F ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b FAYOUM UNIVERSITY   (Egypt)

^c BENI SUEF UNIVERSITY   (Egypt)

^d Cairo University   (Egypt)

Author keywords

autoimmunity; hepatitis C virus; liver fibrosis; Osteopontin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CRYOGLOBULIN; OSTEOPONTIN; RHEUMATOID FACTOR; SERUM ALBUMIN; BIOLOGICAL MARKER;

ADULT; AGE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RHEUMATIC DISEASE; SYSTEMIC VASCULITIS; VIRUS LOAD; BLOOD; CRYOGLOBULINEMIA; HEPATITIS C VIRUS; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RHEUMATOID ARTHRITIS; SEVERITY OF ILLNESS INDEX; VIROLOGY;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CRYOGLOBULINEMIA; CRYOGLOBULINS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OSTEOPONTIN; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; SYSTEMIC VASCULITIS; VIRAL LOAD;

EID: 84878323538     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9727-7     Document Type: Article

References (38)

1. Scatena M, Liaw L, Giachelli CM. Osteopontin. A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2302-9.
2. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008;19(5-6):333-45.
3. Cho HJ, Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 2009;11(3):206-13.
4. Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal. 2009;3:311-22.
5. Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, Fukuda K, Kanai H, Nakashima H, Otsuka T, Hirakata H. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum. 2001;44:2097-106.
6. Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, Kobayashi H, Shimizu M, Katada Y, Wakitani S, Murata N, Nomura S, Matsuno H, Katayama R, Kon S, Inobe M, Uede T, Kawase I, Saeki Y. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol. 2002;29:2061-7.
7. Lorenzen J, Lovric S, Krämer R, Haller H, Haubitz M. Osteopontin in antineutrophil cytoplasmic autoantibody-associated vasculitis: relation to disease activity, organ manifestation and immunosuppressive therapy. Ann Rheum Dis. 2010;69(6):1169-7.
8. Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci. 2002;25:491-505.
9. Lorenzen JM, Krämer R, Meier M, Werfel T, Wichmann K, Hoeper MM, Riemekasten G, Becker MO, Haller H, Witte T. Osteopontin in the development of systemic sclerosis-relation to disease activity and organ manifestation. Rheumatology (Oxford). 2010;49(10):1989-91.
10. Erturkler E, CIcek D, Kaman D, Ozdogan S, Bakar DertlIoglu S. Plasma osteopontin levels in patients with Behcet's disease and psoriasis. Eur J Dermatol. 2011;21(2):203-8.
11. Medica A, Salobir B, Tercelj M, Peterlin B. Genetic variation in osteopontin gene is associated with susceptibility to sarcoidosis in Slovenian population. Dis Markers. 2009;27(6):295-302.
12. Arai M, Yokosuka O, Kanda T, Fukai K, Imazeki F, Muramatsu M, Seki N, Miyazaki M, Ochiai T, Hirasawa H, Saisho H. Serum osteopontin levels in patients with acute liver dysfunction. Scand J Gastroenterol. 2006;41(1):102-10.
13. Matsui A, Mochida S, Ohno A, Nagoshi S, Hirose T, Fujiwara K. Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol Res. 2004;29(4):202-6.
14. Huang W, Zhu G, Huang M, Lou G, Liu Y, Wang S. Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. Clin Chim Acta. 2010;411(9-10):675-8.
15. Bessa SS, Elwan NM, Suliman GA, El-Shourbagy SH. Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. Arch Med Res. 2010;41(7):541-7.
16. Libra M, Indelicato M, De Re V, Zignego AL, Chiocchetti A, Malaponte G, Dianzani U, Nicoletti F, Stivala F, McCubrey JA, Mazzarino MC. Elevated serum levels of osteopontin in HCV-associated lymphoproliferative disorders. Cancer Biol Ther. 2005;4(11):1192-4.
17. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. PNAS. 2010;107:14757-62.
18. Jimenez-Sousa MA, Almansa R, de la Fuente C, Caro-Paton A, Ruiz L, Sanchez-Antolín G, Gonzalez JM, Aller R, Alcaide N, Largo P, Resino S, de Lejarazu RO, Bermejo-Martin JF. Down-modulation of Th1, Th17 responses after treatment in hepatitis C virus infection. Eur Cytokine Netw. 2010;21(2):84-91.
19. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010;8(12):1017-29.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatol. 1996;24:289-93.
21. Okamoto H, Okada S, Sugiyama Y, Tanaka T, Sugai Y, Akahane Y, Machida A, Mishiro S, Yoshizawa H, Miyakawa Y. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5'-noncoding region. Jpn J Exp Med. 1990;60:215-22.
22. Mochida S, Yoshimoto T, Mimura S, Inao M, Matsui A, Ohno A, Koh H, Saitoh E, Nagoshi S, Fujiwara K. Transgenic mice expressing osteopontin in hepatocytes as a model of autoimmune hepatitis. Biochem Biophys Res Commun. 2004;317:114-20.
23. Saitoh E, Matsui A, Inao M, Mimura S, Koh H, Ohno A, Nagoshi S, Kayano H, Yoshimoto T, Mochida S, Fujiwara K. Extrahepatic manifestations in transgenic mice of osteopontin in hepatocytes - A clue to advent of pathological state in various organs of chronic hepatitis C patients. Hepatol Res. 2005;31:197-202.
24. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14:2037-44.
25. Zignego AL. Enhanced TH1 cytokine production in hepatitis C virus-infected patients with mixed cryoglobulinemia: understanding the pathological issue. J Hepatol. 2004;41:1045-9.
26. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem. 2001;276:46024-30.
27. Suzuki H, Amizuka N, Oda K, Li M, Yoshie H, Ohshima H, Noda M, Maeda T. Histological evidence of the altered distribution of osteocytes and bone matrix synthesis in klotho-deficient mice. Arch Histol Cytol. 2005;68:371-81.
28. Whitington PF, Malladi P, Melin-Aldana H, Azzam R, Mack CL, Sahai A. Expression of osteopontin correlates with portal biliary proliferation and fibrosis in biliary atresia. Pediatr Res. 2005;57:837-44.
29. Patouraux S, Bonnafous S, Voican CS, Anty R, Saint-Paul MC, Rosenthal-Allieri MA, Agostini H, Njike M, Barri-Ova N, Naveau S, Le Marchand-Brustel Y, Veillon P, Calès P, Perlemuter G, Tran A, Gual P. The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One. 2012;7(4):e35612.
30. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, Mi Z, Pereira TA, Zdanowicz M, Malladi P, Chen Y, Moylan C, Jung Y, Bhattacharya SD, Teaberry V, Omenetti A, Abdelmalek MF, Guy CD, Adams DH, Kuo PC, Michelotti GA, Whitington PF, Diehl AM. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology. 2011;53(1):106-15.
31. Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, Xie G, Philips G, Chan IS, Karaca GF, Pereira TD, Chen Y, Mi Z, Kuo PC, Choi SS, Guy CD, Abdelmalek MF, Diehl AM (2012) NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut. Mar 17. [Epub ahead of print]
32. Zhao L, Li T, Wang Y, Pan Y, Ning H, Hui X, Xie H, Wang J, Han Y, Liu Z, Fan D. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract. 2008;62(7):1056-62.
33. Johnston NI, Gunasekharan VK, Ravindranath A, O'Connell C, Johnston PG, El-Tanani MK. Osteopontin as a target for cancer therapy. Front Biosci. 2008;13:4361-72.
34. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatol. 2012;55:483-90.
35. Shahin AA, El Desouky SM, Zayed HS. A retrospective analysis of treatment outcomes in patients with hepatitis C related systemic vasculitis receiving intravenous methylprednisolone and cyclophosphamide. Clin Rheumatol. 2011;30(5):607-14.
36. Cacoub P, Saadoun D, Sene D, Limal N, Piette JC. Treatment of hepatitis C virus related systemic vasculitis. J Rheumatol. 2005;32:11.
37. Yamamoto N, Nakashima T, Torikai M, Naruse T, Morimoto J, Kon S, Sakai F. Successful treatment of collagen-induced arthritis in nonhuman primates by chimeric anti-osteopontin antibody. Int Immunopharmacol. 2007;7:1460-70.
38. Nguyen M, Keeffe E. Chronic hepatitis C: genotypes 4 to 9. Clin Liver Dis. 2005;9(3):411-26.